Premium
Calcium Channel Blocker Use and the Risk for Prostate Cancer: A Population‐Based Nested Case‐Control Study
Author(s) -
Rotshild Victoria,
Azoulay Laurent,
Feldhamer Ilan,
Perlman Amichai,
Muszkat Mordechai,
Matok Ilan
Publication year - 2019
Publication title -
pharmacotherapy: the journal of human pharmacology and drug therapy
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.227
H-Index - 109
eISSN - 1875-9114
pISSN - 0277-0008
DOI - 10.1002/phar.2266
Subject(s) - medicine , nested case control study , odds ratio , cohort , confidence interval , population , logistic regression , prostate cancer , cohort study , incidence (geometry) , cancer , environmental health , physics , optics
Calcium channels play a significant role in the regulation of cell proliferation and apoptosis. This study investigates associations between calcium channel blocker ( CCB ) use and the incidence of prostate cancer ( PC a). Methods A nested case‐control study was conducted using the Clalit Health Services database. We formed a population‐based cohort of patients who were prescribed their first antihypertensive agent between 2000 and 2014. For each newly diagnosed PC a case in the cohort, 10 controls were matched by age, calendar year of cohort entry, and duration of follow‐up. Multivariate conditional logistic regression analyses were used to evaluate the odds ratios ( OR s) of PC a among CCB users compared with users of other antihypertensive drugs. Results We identified 4346 patients with newly diagnosed PC a during the median follow‐up of 5.3 years. The exposure to CCB s was associated with a slight increase in risk for PC a ( OR 1.10, 95% confidence interval [ CI] 1.02–1.18) when compared with non‐ CCB antihypertensive drugs. In secondary analyses, evidence was found of a duration‐response relationship, with the association for PC a increasing by 27% for every 10‐year increment of CCB use ( OR 1.27, 95% CI 1.04–1.56). Conclusions The results of this large population‐based study indicate a modest but significant increase in the risk of PC a among CCB users, and the risk increases with duration of use.